icon-folder.gif   Conference Reports for NATAP  
 
  2019 AASLD/EASL HCV
Special Conference 01-02
February 2019, Miami, FL
Back grey_arrow_rt.gif
 
 
 
Real-World Health Care Resource Utilization and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies - AASLD/EASL Special HCV Conference Miami
 
 
  Reported by Jules Levin
 
AASLD/EASL HCV Special Conference, February 1-2, 2019, Miami, Florida, United States
 
Alessio Aghemo1, Stefan Bourgeois2, Michael Gschwantler3, Yuri Sanchez Gonzalez4, Lois Larsen4, Mark Bondin4, Rawi Hazzan5, Lorenzo Magenta6, Tarik Asselah7 1Humanitas University and Research Hospital, Rozzano, Italy; 2Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium; 3Department of Internal Medicine IV, Wilhelminenspital, and Sigmund Freud University, Vienna, Austria; 4AbbVie Inc., North Chicago, Illinois, United States; 5Emek Medical Center, Afula, Israel; 6Epatocentro Ticino, Lugano, Switzerland; 7Hopital Beaujon & INSERM UMR 1149, Clichy, France

0204191

0204192

0204193

0204194

0204195

0204196

0204197

0204198

0204199